Plant Name: Caragana sinica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; | |
| PTPN1; PTPN2; CDC25B; | |
| PLA2G1B; TDP1; PIK3CA; PIK3CB; PKM; GFER; NQO2; AKR1B10; USP2; POLB; | |
| CA2; CA1; CA12; CA9; CA13; CA5B; CA3; CA14; CA5A; CA4; CA6; CA7; | |
| ESR1; | |
| NR1H4; | |
| PPARG; | |
| PTGS1; MAOA; PTGS2; | |
| HIF1A; TP53; | |
| SLC6A2; | |
| HTT; LMNA; APP; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLC6A2 | Norepinephrine transporter | P23975 | CHEMBL222 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.280E-13 | 6.493E-10 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, NQO2, NR1H4, PPARG, PTPN1, TP53 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.886E-10 | 4.489E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 9.435E-09 | 1.081E-05 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 2.600E-08 | 2.831E-05 | CA2, CA7, HIF1A, HTT, NR1H4, PIK3CB, PLA2G1B, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.818E-08 | 3.779E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 5.176E-08 | 4.901E-05 | AKR1B10, APP, CYP1A2, CYP2C19, CYP2C9, CYP3A4, ESR1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.633E-07 | 1.077E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, NQO2, PTGS1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.247E-07 | 2.020E-04 | CYP1A2, CYP2C19, CYP2C9, CYP3A4, PTGS1, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 8.751E-07 | 4.648E-04 | APP, CA12, CA2, CA7, ESR1, HIF1A, HTT, PIK3CB, PLA2G1B, TP53 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.135E-06 | 5.617E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.074E-06 | 9.586E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.926E-31 | 1.944E-26 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 2.851E-06 | 1.171E-03 | APP, CA2, CA7, ESR1, HIF1A, HTT, PIK3CB, PLA2G1B, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.696E-06 | 1.171E-03 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 4.616E-06 | 1.759E-03 | PTGS1, PTGS2 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 7.136E-06 | 2.466E-03 | CA2, CA7, HIF1A, HTT, NR1H4, PIK3CB, PLA2G1B, PTGS2 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.237E-05 | 3.848E-03 | POLB, PPARG, TP53 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.237E-05 | 3.848E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.383E-05 | 4.125E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.383E-05 | 4.125E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.383E-05 | 4.125E-03 | GPBAR1, NR1H4 |
| BP | GO:0009987; cellular process | GO:2001242; regulation of intrinsic apoptotic signaling pathway | 2.290E-05 | 6.475E-03 | HIF1A, PTGS2, PTPN1, PTPN2, TP53 |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 2.360E-05 | 6.506E-03 | HIF1A, NR1H4, PIK3CA, PPARG, PTPN2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.762E-05 | 7.302E-03 | PTPN1, PTPN2 |
| MF | GO:0005488; binding | GO:0019899; enzyme binding | 3.060E-05 | 7.571E-03 | APP, CDC25B, CYP1A2, CYP2C19, CYP3A4, ESR1, HIF1A, HTT, POLB, PPARG, PTGS2, PTPN1, PTPN2, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0001816; cytokine production | 3.132E-05 | 7.579E-03 | APP, HIF1A, PLA2G1B, PTGS2 |
| BP | GO:0032502; developmental process | GO:0048513; animal organ development | 3.371E-05 | 7.892E-03 | CA2, CYP1A2, ESR1, GFER, HIF1A, HTT, PIK3CA, PKM, POLB, PPARG, USP2 |
| BP | GO:0008283; cell proliferation | GO:0048145; regulation of fibroblast proliferation | 3.603E-05 | 8.258E-03 | ESR1, PLA2G1B, PPARG, TP53 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.968E-23 | 4.321E-19 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.105E-22 | 3.539E-18 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 7.973E-30 | 1.132E-27 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.652E-09 | 2.593E-07 | CYP2C9; PLA2G1B; CYP1A2; CYP3A4; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.891E-07 | 6.714E-06 | CYP2C9; PLA2G1B; CYP2C19; PTGS2; PTGS1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.199E-07 | 5.677E-06 | CYP2C9; APP; MAOA; CYP2C19; PTGS2; PTGS1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.801E-07 | 7.691E-06 | PKM; PIK3CA; PIK3CB; TP53; HIF1A |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.250E-07 | 7.691E-06 | CYP2C9; MAOA; CYP1A2; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 7.733E-07 | 1.569E-05 | CYP2C9; CYP1A2; CYP3A4; CYP2C19; PTGS2 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.691E-06 | 8.326E-05 | PIK3CA; PIK3CB; TP53; ESR1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 5.700E-06 | 8.993E-05 | PIK3CA; PIK3CB; PTGS2; PTGS1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.428E-05 | 7.355E-04 | PIK3CA; PIK3CB; TP53; HIF1A; ESR1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.148E-05 | 4.471E-04 | PIK3CA; PIK3CB; PTGS2; TP53 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 4.467E-05 | 5.766E-04 | PIK3CA; PPARG; PIK3CB; TP53 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.734E-05 | 7.355E-04 | POLB; PKM; PIK3CA; PIK3CB; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.688E-04 | 1.572E-03 | PIK3CA; PPARG; PIK3CB; PTGS2; HIF1A; TP53 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.907E-04 | 1.593E-03 | CYP2C9; PKM; AKR1B10; PLA2G1B; MAOA; CYP1A2; PTGS2; CYP2C19; CYP3A4; PTGS1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.094E-04 | 1.651E-03 | PIK3CA; LMNA; PIK3CB; TP53 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.395E-04 | 1.415E-03 | PKM; PIK3CA; PIK3CB |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.772E-04 | 1.572E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.209E-04 | 1.651E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.711E-04 | 1.925E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.847E-04 | 1.925E-03 | PIK3CA; PIK3CB; PTGS2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.436E-04 | 1.963E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 2.988E-04 | 1.928E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.594E-04 | 1.963E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.594E-04 | 1.963E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.436E-04 | 1.963E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.456E-04 | 2.215E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.643E-04 | 2.215E-03 | PIK3CA; PIK3CB; ESR1 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.625E-04 | 3.827E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.835E-04 | 2.215E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.140E-03 | 4.762E-03 | PIK3CA; PIK3CB; CDC25B |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.456E-04 | 2.215E-03 | CA2; NR1H4; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.835E-04 | 2.215E-03 | CYP2C9; CYP1A2; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.174E-03 | 4.763E-03 | PIK3CA; PIK3CB; ESR1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.244E-03 | 4.906E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.316E-03 | 5.051E-03 | PIK3CA; PIK3CB; HIF1A |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.590E-03 | 5.789E-03 | PIK3CA; PIK3CB; PTGS2 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.549E-03 | 5.787E-03 | PTPN1; PIK3CA; PIK3CB |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.061E-03 | 6.804E-03 | POLB; PIK3CA; PIK3CB; TP53 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.039E-03 | 6.804E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.137E-03 | 6.898E-03 | PIK3CA; PIK3CB; PTGS1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.039E-03 | 6.804E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.673E-03 | 8.250E-03 | PIK3CA; PPARG; PIK3CB |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 2.239E-03 | 7.064E-03 | PIK3CA; PPARG; PIK3CB |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 2.909E-03 | 8.604E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 2.731E-03 | 8.250E-03 | PIK3CA; PIK3CB; TP53 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.422E-03 | 9.345E-03 | PIK3CA; PTGS2; TP53; CDC25B |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.552E-03 | 9.517E-03 | PIK3CA; PIK3CB; TP53 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 3.093E-03 | 8.785E-03 | PTPN1; PIK3CA; PIK3CB |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 4.431E-03 | 1.124E-02 | PIK3CA; PIK3CB; PTGS2 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 4.431E-03 | 1.124E-02 | PIK3CA; PIK3CB; PTPN2 |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 7.704E-03 | 1.854E-02 | HTT; PPARG; TP53 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.725E-03 | 2.031E-02 | PIK3CA; PIK3CB; TP53 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.196E-02 | 2.535E-02 | PIK3CA; PLA2G1B; PIK3CB |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.907E-02 | 3.659E-02 | PIK3CA; PIK3CB |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.802E-02 | 3.553E-02 | PIK3CA; PIK3CB |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.632E-02 | 3.359E-02 | PIK3CA; PIK3CB |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.439E-02 | 3.005E-02 | PIK3CA; PIK3CB |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.275E-02 | 4.142E-02 | PIK3CA; PIK3CB |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 8.984E-03 | 2.058E-02 | PIK3CA; PIK3CB |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.030E-02 | 2.284E-02 | PIK3CA; PIK3CB |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.871E-02 | 3.640E-02 | PIK3CA; PIK3CB |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.087E-02 | 3.849E-02 | PIK3CA; PIK3CB |
| hsa04070 | Phosphatidylinositol signaling system_Homo sapiens_hsa04070 | 1.802E-02 | 3.553E-02 | PIK3CA; PIK3CB |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.014E-02 | 3.764E-02 | PIK3CA; PIK3CB |
| hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 1.733E-02 | 3.516E-02 | CA2; PLA2G1B |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.014E-02 | 3.764E-02 | PIK3CA; PIK3CB |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.549E-02 | 4.524E-02 | PIK3CA; PIK3CB |
| hsa00562 | Inositol phosphate metabolism_Homo sapiens_hsa00562 | 9.761E-03 | 2.200E-02 | PIK3CA; PIK3CB |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.794E-02 | 4.897E-02 | TP53; CDC25B |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 7.993E-03 | 1.892E-02 | PIK3CA; PIK3CB |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.169E-02 | 2.515E-02 | PIK3CA; PIK3CB |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.549E-02 | 4.524E-02 | PIK3CA; PIK3CB |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.387E-03 | 1.591E-02 | PIK3CA; PIK3CB |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 6.606E-03 | 1.617E-02 | CYP1A2; CYP3A4 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.686E-03 | 5.986E-03 | PPARG; TP53 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 3.037E-03 | 8.785E-03 | PIK3CA; PIK3CB |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 4.025E-03 | 1.058E-02 | PIK3CA; PIK3CB |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.192E-03 | 8.889E-03 | MAOA; CYP1A2 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.059E-03 | 4.558E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.046E-02 | 2.284E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Neuroblastoma | C74.1, C74.9, C75.4, C75.5, D35.0, D35.5, D35.6, D44.6, D44.7 | SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; SLC6A2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1; PKM |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; PTGS2; PTGS2; PTGS2; PLA2G1B |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; HIF1A; PIK3CA; PIK3CB; CA9; PKM |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; PTGS2; PPARG; PPARG |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | SLC6A2; SLC6A2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; PLA2G1B; PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | SLC6A2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; PTGS2; PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; SLC6A2; MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; SLC6A2; PPARG |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | SLC6A2; MAOA; MAOA |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; PTGS2; APP; PPARG; PPARG |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; PPARG |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | SLC6A2 |
| H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | SLC6A2; SLC6A2; SLC6A2; SLC6A2; MAOA |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | SLC6A2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; PIK3CA |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | SLC6A2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | TP53; HIF1A; PIK3CA; PIK3CB; CA1; CA9; ESR1; ESR1; NQO2; PTGS2; CDC25B; APP |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cancer pain | R52, G89 | SLC6A2 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; PTGS1; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; PPARG |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| NA: NA | Geographic retinal atrophy | NA | APP |
| C00-D49: Neoplasms | Glioma | C71 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | APP |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; PTGS1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; PPARG |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; APP |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2; PTGS1 |
| C00-D49: Neoplasms | Neuroendocrine cancer | C7A | SLC6A2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; PTGS1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; ESR1; ESR1; NQO2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |